首页> 外文期刊>World Journal of Gastroenterology >Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
【24h】

Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?

机译:肝细胞癌:具有g酸增强磁共振和弥散加权成像的LI-RADS v2017是否可以提高诊断准确性?

获取原文
           

摘要

BACKGROUND The Liver Imaging Reporting and Data System (LI-RADS), supported by the American College of Radiology (ACR), has been developed for standardizing the acquisition, interpretation, reporting, and data collection of liver imaging examinations in patients at risk for hepatocellular carcinoma (HCC). Diffusion-weighted imaging (DWI), which is described as an ancillary imaging feature of LI-RADS, can improve the diagnostic efficiency of LI-RADS v2017 with gadoxetic acid-enhanced magnetic resonance imaging (MRI) for HCC. AIM To determine whether the use of DWI can improve the diagnostic efficiency of LI-RADS v2017 with gadoxetic acid-enhanced magnetic resonance MRI for HCC. METHODS In this institutional review board-approved study, 245 observations of high risk of HCC were retrospectively acquired from 203 patients who underwent gadoxetic acid-enhanced MRI from October 2013 to April 2018. Two readers independently measured the maximum diameter and recorded the presence of each lesion and assigned scores according to LI-RADS v2017. The test was used to determine the agreement between the two readers with or without DWI. In addition, the sensitivity (SE), specificity (SP), accuracy (AC), positive predictive value (PPV), and negative predictive value (NPV) of LI-RADS were calculated. Youden index values were used to compare the diagnostic performance of LI-RADS with or without DWI. RESULTS Almost perfect interobserver agreement was obtained for the categorization of observations with LI-RADS ( kappa value: 0.813 without DWI and 0.882 with DWI). For LR-5, the diagnostic SE, SP, and AC values were 61.2%, 92.5%, and 71.4%, respectively, with or without DWI; for LR-4/5, they were 73.9%, 80%, and 75.9% without DWI and 87.9%, 80%, and 85.3% with DWI; for LR-4/5/M, they were 75.8%, 58.8%, and 70.2% without DWI and 87.9%, 58.8%, and 78.4% with DWI; for LR- 4/5/TIV, they were 75.8%, 75%, and 75.5% without DWI and 89.7%, 75%, and 84.9% with DWI. The Youden index values of the LI-RADS classification without or with DWI were as follows: LR-4/5: 0.539 vs 0.679; LR-4/5/M: 0.346 vs 0.467; and LR-4/5/TIV: 0.508 vs 0.647. CONCLUSION LI-RADS v2017 has been successfully applied with gadoxetate-enhanced MRI for patients at high risk for HCC. The addition of DWI significantly increases the diagnostic efficiency for HCC.
机译:背景技术由美国放射学会(ACR)支持的肝成像报告和数据系统(LI-RADS)已开发用于标准化肝细胞风险患者的肝成像检查的采集,解释,报告和数据收集。癌(HCC)。扩散加权成像(DWI)被描述为LI-RADS的辅助成像功能,可以通过牛ado酸增强磁共振成像(MRI)提高LI-RADS v2017对HCC的诊断效率。目的确定使用DWI能否通过牛ado酸增强磁共振MRI对HCC进行LI-RADS v2017诊断。方法在该机构审查委员会批准的研究中,回顾性地从2013年10月至2018年4月接受gaxxetic acid增强MRI的203例患者中获得245例HCC高危观察结果。两名读者独立测量了最大直径并记录了每个根据LI-RADS v2017进行病变和指定评分。该测试用于确定使用或不使用DWI的两个阅读器之间的协议。另外,计算了LI-RADS的敏感性(SE),特异性(SP),准确性(AC),阳性预测值(PPV)和阴性预测值(NPV)。使用尤登指数值比较具有或不具有DWI的LI-RADS的诊断性能。结果对于使用LI-RADS进行的观察分类,获得了几乎完美的观察者间一致性(kappa值:DWI为0.813,DWI为0.882)。对于LR-5,在有或没有DWI的情况下,诊断SE,SP和AC值分别为61.2%,92.5%和71.4%。对于LR-4 / 5,无DWI时分别为73.9%,80%和75.9%,有DWI时分别为87.9%,80%和85.3%。对于LR-4 / 5 / M,无DWI时分别为75.8%,58.8%和70.2%,无DWI时分别为87.9%,58.8%和78.4%。对于LR-4 / 5 / TIV,无DWI时分别为75.8%,75%和75.5%,无DWI时分别为89.7%,75%和84.9%。不具有或具有DWI的LI-RADS分类的尤登指数值如下:LR-4 / 5:0.539与0.679; LR-4 / 5 / M:0.346和0.467; LR-4 / 5 / TIV:0.508与0.647。结论LI-RADS v2017已成功地与加多西特增强MRI一起用于高风险肝癌患者。 DWI的添加显着提高了HCC的诊断效率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号